<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21136" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Enoxaparin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jupalli</surname>
            <given-names>Aamani</given-names>
          </name>
          <aff>Oak Hill Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Iqbal</surname>
            <given-names>Arshad Muhammad</given-names>
          </name>
          <aff>Oak Hill Hospital, Brooksville, FL</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aamani Jupalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arshad Muhammad Iqbal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21136.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Enoxaparin is low molecular weight heparin (LMWH) and was first approved for medical use in 1993 and is derived from heparin. It has FDA approval for the following clinical conditions - acute coronary syndromes, deep venous thrombosis (DVT) treatment and prophylaxis, treatment for pulmonary embolism (PE), venous thromboembolism (VTE) treatment, and prophylaxis in a variety of scenarios, percutaneous coronary intervention (PCI), and periprocedural anticoagulation, among others. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of enoxaparin, pertinent for interprofessional team members in treating patients with conditions where this agent is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the therapeutic mechanism of action of enoxaparin.</p></list-item><list-item><p>Review the many indications for enoxaparin use.</p></list-item><list-item><p>Summarize the adverse event profile of enoxaparin use.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients when using enoxaparin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21136&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21136">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21136.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Two low molecular heparins are available&#x000a0;in the United States: dalteparin and enoxaparin. Enoxaparin is low molecular weight&#x000a0;heparin (LMWH) and was first approved for medical use in 1993 and is derived&#x000a0;from&#x000a0;heparin.</p>
        <p>
<bold>FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prophylaxis of deep vein thrombosis (DVT) in hip replacement surgery, abdominal surgery, knee replacement surgery, or medical patients with severely limited mobility during acute illness<xref ref-type="bibr" rid="article-21136.r1">[1]</xref><xref ref-type="bibr" rid="article-21136.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Inpatient management of acute deep vein thrombosis with or without pulmonary embolism<xref ref-type="bibr" rid="article-21136.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Outpatient management of acute deep vein thrombosis without pulmonary embolism<xref ref-type="bibr" rid="article-21136.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Prophylaxis of ischemic complications of Non-ST-elevation myocardial infarction (NSTEMI) and unstable angina<xref ref-type="bibr" rid="article-21136.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of acute ST-segment elevation myocardial infarction managed medically or with the subsequent percutaneous coronary intervention<xref ref-type="bibr" rid="article-21136.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-label Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary prevention of venous thromboembolism (VTE)</p>
          </list-item>
          <list-item>
            <p>Treatment for prosthetic&#x000a0;valve thrombosis in pregnancy</p>
          </list-item>
          <list-item>
            <p>Treatment for VTE in pregnancy<xref ref-type="bibr" rid="article-21136.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Antiphospholipid antibody syndrome</p>
          </list-item>
          <list-item>
            <p>Arterial thromboembolism prophylaxis</p>
          </list-item>
          <list-item>
            <p>Cerebral thromboembolism</p>
          </list-item>
          <list-item>
            <p>Periprocedural anticoagulation<xref ref-type="bibr" rid="article-21136.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Venous thromboembolism secondary to malignancy<xref ref-type="bibr" rid="article-21136.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21136.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Enoxaparin is low molecular weight heparin (LMWH) with a mean molecular weight of 4000 to 5000 Daltons. It has a quick onset of action when given in the intravenous form. Enoxaparin is an indirect anticoagulant that binds and potentiates antithrombin III (serine protease inhibitor) through a specific pentasaccharide sequence to form a complex that irreversibly inactivates factor Xa. The primary difference between unfractionated heparin and enoxaparin is their relative inhibition of thrombin (factor-IIa) and factor-Xa. Smaller heparin fragments cannot bind antithrombin and thrombin simultaneously. Due to their smaller chain length and lower molecular weight,&#x000a0;LMWH&#x000a0;has better activity against factor-Xa and inhibits thrombin to a lesser degree. Thus, enoxaparin has less activity against factor IIa (thrombin) than unfractionated heparin. The anti-factor Xa-to-IIa activity ratio for the LMWHs varies from 2:1 to 4:1.<xref ref-type="bibr" rid="article-21136.r10">[10]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Peak&#x000a0;effect of enoxaparin is observed approximately 4 hours after administration. Anti-Factor Xa activity&#x000a0;is detected&#x000a0;in plasma for about 12 hours.<xref ref-type="bibr" rid="article-21136.r11">[11]</xref></p>
        <p><bold>Distribution:&#x000a0;&#x000a0;</bold>The apparent volume of distribution of&#x000a0;enoxaparin&#x000a0;estimated by anti-Factor-Xa activity is approximately 4.3 Liters.</p>
        <p><bold>Metabolism: </bold>It&#x000a0;is metabolized in the liver by desulfation and depolymerization to lower molecular weight fragments with reduced biologic activity.</p>
        <p><bold>Excretion:&#x000a0;</bold>Enoxaparin&#x000a0;follows first-order kinetics and is&#x000a0;eliminated primarily in the urine.&#x000a0;The elimination half-life of enoxaparin&#x000a0;is approximately 3&#x000a0;to 4.5&#x000a0;hours following a single dose.&#x000a0;Following repeated doses, the half-life of enoxaparin increases to&#x000a0;approximately 7 hours. As enoxaparin is primarily eliminated by renal excretion, there is a concern for drug accumulation and bleeding risk in patients with renal impairment.<xref ref-type="bibr" rid="article-21136.r10">[10]</xref><xref ref-type="bibr" rid="article-21136.r12">[12]</xref></p>
      </sec>
      <sec id="article-21136.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Enoxaparin has an advantage over heparin because of its bioavailability. Ninety percent of the drug is available when&#x000a0;given in the subcutaneous&#x000a0;form. Enoxaparin can also be administered in intravenous formulations.<xref ref-type="bibr" rid="article-21136.r10">[10]</xref> The intravenous&#x000a0;formulation should not be mixed or co-administered with other medications. The port should be flushed before use with normal saline or 5% dextrose water. An IV injection is usually given during the primary PCI and at the time of STEMI. Subcutaneous administration should alternate&#x000a0;between the left or right anterolateral and left or right posterolateral abdominal wall. There is a small risk of bruising that can be minimized by not rubbing the injection site. There is no topical form available. Intramuscular administration is generally avoided. One mg&#x000a0;of enoxaparin&#x000a0;is&#x000a0;equal to 100 units of anti-Xa activity. The dose of enoxaparin depends upon indications, adverse events profile, and renal/hepatic impairment.&#x000a0;</p>
        <p><bold>Venous Thromboembolism Prophylaxis: </bold>Recommended dose of enoxaparin is 40 mg SC once daily, according to the ACCP(American&#x000a0;College of Chest Physicians) clinical practice guidelines.<xref ref-type="bibr" rid="article-21136.r13">[13]</xref></p>
        <p><bold><bold>Treatment of Acute Deep Vein Thrombosis&#x000a0;with or without Pulmonary Embolism:<bold>&#x000a0;</bold></bold></bold>The recommended dose of enoxaparin is 1 mg/kg SC every 12 hours or 1.5 mg/kg SC daily. Anticoagulation should be started&#x000a0;immediately in the case of suspected or proven pulmonary embolism. Patients with pulmonary embolism usually require inpatient therapy, according to the PERT Consortium.<xref ref-type="bibr" rid="article-21136.r14">[14]</xref><xref ref-type="bibr" rid="article-21136.r15">[15]</xref></p>
        <p><bold>STEMI:</bold> According to the ACCF/AHA (American College of Cardiology Foundation/American Heart Association) guidelines for ST-elevation myocardial infarction (STEMI), in patients treated with fibrinolytic therapy, doses are&#x000a0;suggested according to age and renal function. If the age of patients &#x0003c;75 years, 30 mg IV bolus, followed in 15 minutes by 1 mg/kg&#x000a0;SC every 12 hours, is recommended. If the age is &#x02265;75 years, no IV bolus is recommended, and&#x000a0; 0.75 mg/kg subcutaneously every 12 h (maximum 75 mg for the first two doses) is administered. For creatinine clearance is &#x0003c;30 mL/min, 1 mg/kg subcutaneously every 24 hours is recommended regardless of age.<xref ref-type="bibr" rid="article-21136.r16">[16]</xref></p>
        <p><bold>NSTEMI:</bold> The suggested dose of enoxaparin in Non-ST-elevation myocardial infarction is&#x000a0;1 mg/kg&#x000a0;SC every 12 hours. Guidelines suggest decreasing the dose of enoxaparin to 1 mg/kg SC once daily in patients with creatinine clearance &#x0003c;30 mL/min. Enoxaparin is continued for the duration of hospitalization or until percutaneous coronary intervention.<xref ref-type="bibr" rid="article-21136.r17">[17]</xref></p>
        <p>
<bold>
<bold>Use in&#x000a0;Specific&#x000a0;Patient Populations</bold>
</bold>
</p>
        <p><bold><bold>Patients with Hepatic Impairment: </bold></bold>A clinical trial demonstrated that enoxaparin decreased the rate of portal vein thrombosis and hepatic decompensation and increased the probability of survival by preventing&#x000a0;microvascular thrombosis in patients with cirrhosis. An increased risk of bleeding on anticoagulation therapy is seen in patients with liver cirrhosis due to disequilibrium between procoagulant and anticoagulant states. In addition, older age, increased INR, female sex, prior history of bleeding, hypertension, peptic ulcer disease, active cancer, hypertension, prior stroke, renal impairment, and alcohol abuse augments the risk of bleeding in patients with cirrhosis. In liver cirrhosis, enoxaparin can increase the&#x000a0;risk of bleeding; caution is required before initiating enoxaparin.<xref ref-type="bibr" rid="article-21136.r18">[18]</xref>&#x000a0;</p>
        <p><bold>Patients with Renal Impairment:&#x000a0;</bold>In patients with renal impairment, increased bleeding tendency is seen due to increased exposure to enoxaparin. Dose adjustment of enoxaparin is recommended in patients with severe renal impairment (creatinine clearance &#x0003c;30 mL/min), with 1 mg/kg once daily and simultaneous monitoring of factor anti-Xa activity. Usually, no dose adjustment is required if&#x000a0;creatinine clearance is &#x0003e;30 mL/min.<xref ref-type="bibr" rid="article-21136.r19">[19]</xref></p>
        <p><bold>Pregnancy Considerations:</bold> Pregnant&#x000a0;women&#x000a0;have&#x000a0;a significantly&#x000a0;increased risk of thromboembolism than&#x000a0;nonpregnant women. Venous thromboembolism (VTE) is the major&#x000a0;cause of maternal mortality in the United States. Enoxaparin&#x000a0;doesn't cross the placenta and is considered safe in pregnancy. According to ACOG (American College of Obstetricians &#x00026; Gynecologists) guidelines, enoxaparin, 40 mg SC once daily, is recommended for VTE prophylaxis. Therapeutic anticoagulation with enoxaparin, 1 mg/kg every 12 hours, is recommended for women with acute thromboembolism during the current pregnancy and women with a history of recurrent thrombosis.<xref ref-type="bibr" rid="article-21136.r7">[7]</xref></p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Available evidence suggests&#x000a0;that maternal enoxaparin in doses up to 40 mg daily does not cause adverse&#x000a0;drug reactions&#x000a0;in breastfed infants.&#x000a0;Enoxaparin has a high&#x000a0;molecular weight and is not expected to be excreted into breast milk or absorbed from the infant's gastrointestinal tract. Therefore, no special precautions are required.<xref ref-type="bibr" rid="article-21136.r20">[20]</xref></p>
        <p><bold>COVID-19 Considerations: </bold>In 2022, the&#x000a0;American Society of Hematology (ASH) guidelines advised using prophylactic intensity over therapeutic-intensity anticoagulation for patients with critical illness due to COVID-19 (who do not have suspected or confirmed venous thromboembolism).&#x000a0;The guidelines suggested&#x000a0;that higher intensity anticoagulation may be&#x000a0;reasonable for patients evaluated to be at low bleeding risk and high thrombotic risk.<xref ref-type="bibr" rid="article-21136.r21">[21]</xref></p>
      </sec>
      <sec id="article-21136.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Enoxaparin&#x000a0;has a&#x000a0;similar&#x000a0;adverse effect profile as heparin. Because of the reduced effectiveness of the antidote (e.g., protamine), bleeding complications can be severe and life-threatening. Following are the important adverse drug reactions of enoxaparin.</p>
        <list list-type="bullet">
          <list-item>
            <p>Bleeding: the most common adverse effect</p>
          </list-item>
          <list-item>
            <p>Heparin-induced&#x000a0;thrombocytopenia<xref ref-type="bibr" rid="article-21136.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Injection site bleeding or pain</p>
          </list-item>
          <list-item>
            <p>Nausea, confusion, headache&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypoaldosteronism</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal&#x000a0;bleeding</p>
          </list-item>
          <list-item>
            <p>Rectal sheath hematoma<xref ref-type="bibr" rid="article-21136.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Osteoporosis<xref ref-type="bibr" rid="article-21136.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity: transaminitis&#x000a0;with the hepatocellular injury pattern (unlikely to cause clinically apparent liver injury)<xref ref-type="bibr" rid="article-21136.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Bullous hemorrhagic dermatitis<xref ref-type="bibr" rid="article-21136.r26">[26]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21136.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Known hypersensitivity to enoxaparin (urticaria, anaphylactoid reactions, anaphylaxis) or any heparin products<xref ref-type="bibr" rid="article-21136.r27">[27]</xref><xref ref-type="bibr" rid="article-21136.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Active major bleeding such as gastrointestinal bleed</p>
          </list-item>
          <list-item>
            <p>History of heparin-induced thrombocytopenia within the past 100 days or presence of circulating antibodies<xref ref-type="bibr" rid="article-21136.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>History of&#x000a0;hypersensitivity to benzyl alcohol in neonates (benzyl alcohol is present in the multiple-dose formulation of enoxaparin)<xref ref-type="bibr" rid="article-21136.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Active gastric or duodenal ulcers<xref ref-type="bibr" rid="article-21136.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Hemorrhagic&#x000a0;cerebrovascular accident</p>
          </list-item>
          <list-item>
            <p>Severe uncontrolled hypertension&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hemophilia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Increased risk of bleeding following the percutaneous coronary&#x000a0;intervention<xref ref-type="bibr" rid="article-21136.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Pregnant patients with mechanical heart valves<xref ref-type="bibr" rid="article-21136.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Elderly patients&#x000a0;due to increased risk of bleeding<xref ref-type="bibr" rid="article-21136.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with extremes of body weight (obesity or low body weight)<xref ref-type="bibr" rid="article-21136.r35">[35]</xref><xref ref-type="bibr" rid="article-21136.r36">[36]</xref><xref ref-type="bibr" rid="article-21136.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Boxed Warning (FDA)</bold>
</p>
        <p>There is an increased risk of epidural and spinal hematoma in patients anticoagulated with low molecular weight heparins (LMWH), including enoxaparin, in patients who are administered neuraxial anesthesia or undergoing spinal puncture.<xref ref-type="bibr" rid="article-21136.r38">[38]</xref>&#x000a0;These hematomas may lead to permanent paralysis. Factors increasing the risk of developing epidural or spinal hematomas include indwelling epidural catheters, advanced age,&#x000a0;renal failure, and concurrent use of drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs, platelet inhibitors, and other anticoagulants. In addition, prior history of traumatic or repeated epidural or spinal puncture and spinal deformities can increase the risk of developing spinal surgery. Therefore, the placement or removal of a spinal catheter should be deferred for at least 12 hours after administering prophylactic doses of enoxaparin. Longer delays (24 hours) are&#x000a0;suggested for patients administered higher therapeutic doses of enoxaparin (dose of enoxaparin 1.5 mg/kg once daily or 1 mg/kg twice daily). A postprocedure dose of enoxaparin should be given four hours after catheter removal.<xref ref-type="bibr" rid="article-21136.r39">[39]</xref><xref ref-type="bibr" rid="article-21136.r40">[40]</xref><xref ref-type="bibr" rid="article-21136.r41">[41]</xref></p>
      </sec>
      <sec id="article-21136.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Bleeding</bold>
</p>
        <p>The patient should be monitored closely&#x000a0;for signs and symptoms of bleeding. Advanced age, female sex,&#x000a0;and concomitant use of&#x000a0;antiplatelet&#x000a0;drugs are the most&#x000a0;common risk factors for bleeding. Bleeding&#x000a0;is less common with enoxaparin, so monitoring factor Xa is unnecessary in most cases. If bleeding is suspected, an anti-factor&#x000a0;Xa&#x000a0;level can be measured to adjust the dose accordingly, but it does not correlate with an impact on clinical outcome. Renal failure and obesity are the most common indication to monitor enoxaparin as it increases&#x000a0;the chances of bleeding.<xref ref-type="bibr" rid="article-21136.r42">[42]</xref></p>
        <p>Enoxaparin has a good safety and side effect profile. Dose&#x000a0;adjustment&#x000a0;is necessary for advanced age and renal insufficiency. A therapeutic&#x000a0;dose is usually 1 mg/kg every 12 hours, but dose&#x000a0;adjustment&#x000a0;is required&#x000a0;if&#x000a0;the patient is over&#x000a0;75 years old. ACCP guidelines suggest that the anti-Xa levels should be measured 4 hours after enoxaparin administration at a steady state.<xref ref-type="bibr" rid="article-21136.r43">[43]</xref></p>
        <p>
<bold>Thrombocytopenia</bold>
</p>
        <p>Thrombocytopenia&#x000a0;can occur, but it is less&#x000a0;common than&#x000a0;conventional&#x000a0;heparin. If&#x000a0;the patient develops heparin-induced thrombocytopenia (HIT), the drug should be discontinued, and the platelet count monitored.</p>
        <p>
<bold>Renal impairment</bold>
</p>
        <p>Enoxaparin dose requires adjustment with a creatinine clearance of less than 30 mL/minute.<xref ref-type="bibr" rid="article-21136.r44">[44]</xref></p>
        <p>
<bold>Surgery</bold>
</p>
        <p>According to the American&#x000a0;College of Chest Physicians, a last presurgical dose of enoxaparin should be administered&#x000a0;at least&#x000a0;24 hours before surgery. Treatment can be restarted 12 hours after surgery if indicated.<xref ref-type="bibr" rid="article-21136.r8">[8]</xref></p>
      </sec>
      <sec id="article-21136.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Clinical practice guidelines recommend protamine sulfate for the reversal of enoxaparin-associated bleeds dependent on the time from the last administration and dose of enoxaparin. Protamine sulfate is a cationic peptide that binds to low molecular weight heparin, forming an ionic complex with no anticoagulant activity.<xref ref-type="bibr" rid="article-21136.r45">[45]</xref>&#x000a0;The use&#x000a0;of protamine sulfate correlates with fewer bleeding complications post PCI.&#x000a0;</p>
        <p>As with most anticoagulants, bleeding is the major complication with low molecular weight heparin-like enoxaparin. The incidence rate is reported to be less than 3%. Given the subcutaneous administration of LMWH, there is a high risk of minor bruising at the injection site. The subcutaneous injection has a bioavailability of around 100%. In the event of significant bleeding, protamine sulfate can be used to reverse the anticoagulant effects of LMWH partially. Protamine neutralizes about 60% of LMWH anticoagulant activity. For LMWH administered within the previous 8 hours, the recommended dose is 1mg protamine sulfate per 1mg of enoxaparin or 100 anti-factor-Xa units of&#x000a0;dalteparin.<xref ref-type="bibr" rid="article-21136.r42">[42]</xref><bold>&#x000a0;</bold></p>
        <p>According to the ACCP guidelines, the maximum single dose of protamine sulfate is 50 mg. If bleeding persists, a second dose of 50 mg protamine sulfate can be administered. Smaller doses of protamine sulfate can be&#x000a0;administered&#x000a0;if the time since LMWH administration is&#x000a0;greater&#x000a0;than 8 hours.<xref ref-type="bibr" rid="article-21136.r43">[43]</xref>&#x000a0;Universal Heparin Reversal Agent (UHRA) is specifically invented to neutralize the activity of heparin-based anticoagulants. UHRA is a synthetic multivalent polymer that is currently&#x000a0;in clinical trials. The&#x000a0;preliminary&#x000a0;results are promising, showing that UHRA directly binds UFH and enoxaparin and can reverse the activity of heparin and enoxaparin.<xref ref-type="bibr" rid="article-21136.r46">[46]</xref></p>
        <p>Heparin-induced thrombocytopenia is an infrequent but potentially life-threatening&#x000a0;complication of enoxaparin therapy. The development of antibodies against heparin-bound platelet factor 4 (PF4) generally occurs 5&#x02013;10 days after administration. The antibody-heparin-PF4 complex binds&#x000a0;and activates platelets resulting in thrombosis and thrombocytopenia.&#x000a0;4T score (thrombocytopenia, timing of platelet count fall, thrombosis, other causes of thrombocytopenia), serotonin release assay, and&#x000a0;anti-PF4/heparin antibodies are used for diagnosis.<xref ref-type="bibr" rid="article-21136.r47">[47]</xref><xref ref-type="bibr" rid="article-21136.r48">[48]</xref>&#x000a0;Argatroban and&#x000a0;lepirudin direct thrombin inhibitors are FDA-approved for the treatment of HIT.<xref ref-type="bibr" rid="article-21136.r49">[49]</xref>&#x000a0;Argatroban therapy decreased amputation, thrombotic complications, and mortality in clinical trials. Bivalirudin is used for patients undergoing percutaneous cardiac intervention having HIT or at risk for developing HIT. (American society of hematology)<xref ref-type="bibr" rid="article-21136.r22">[22]</xref></p>
      </sec>
      <sec id="article-21136.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing bleeding complications of enoxaparin is challenging. It requires collaboration between interprofessional health care team members such as clinicians (MD, DO, NP, PA), specialists, nurses, laboratory technicians, and pharmacists. The management of bleeding should not be delayed, and intervention should ensue as soon as possible. A blood bank should be contacted for the potential need for an urgent transfusion. As discussed above, protamine sulfate is the drug of choice in this situation. A conservative approach is necessary for the consideration of acute bleeding. Anticoagulation should be stopped with the reversal&#x000a0;of anticoagulation. Fluid resuscitation is also essential if the patient is hemodynamically unstable.</p>
        <p>The nurse should explain the procedure to the patient if the clinician prescribes enoxaparin for home administration. The pharmacist should consult with the prescriber regarding dosing; this should be with the initial prescription of enoxaparin and protamine in the event of reversal. The patient should receive education to report to the emergency department if any signs or symptoms of bleeding occur. Interprofessional collaboration is vital&#x000a0;to improving patient outcomes related to enoxaparin therapy. All team members must maintain open communication with the rest of the care team and keep accurate records regarding enoxaparin therapy. The study reported&#x000a0;a significant decrease in venous thromboembolism in hospitalized patients with an interprofessional team of hospitalists, intensivists, vascular, trauma, orthopedic surgeons, nurses, an inpatient pharmacy director, and a clinical pharmacist.<xref ref-type="bibr" rid="article-21136.r50">[50]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-21136.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21136&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21136">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21136/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21136">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21136.s11">
        <title>References</title>
        <ref id="article-21136.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Venous Thromboembolic Prophylaxis After Total Hip and Knee Arthroplasty.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>2021</year>
            <month>Aug</month>
            <day>18</day>
            <volume>103</volume>
            <issue>16</issue>
            <fpage>1556</fpage>
            <page-range>1556-1564</page-range>
            <pub-id pub-id-type="pmid">34133395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segon</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Summey</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Slawski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaatz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Surgical venous thromboembolism prophylaxis: clinical practice update.</article-title>
            <source>Hosp Pract (1995)</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>248</fpage>
            <page-range>248-257</page-range>
            <pub-id pub-id-type="pmid">32589468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Skulec</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jobanek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cerny</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study.</article-title>
            <source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source>
            <year>2022</year>
            <month>May</month>
            <volume>166</volume>
            <issue>2</issue>
            <fpage>204</fpage>
            <page-range>204-210</page-range>
            <pub-id pub-id-type="pmid">34042098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schomburg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krishna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soubra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cotter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy.</article-title>
            <source>Urol Oncol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>77.e9</fpage>
            <page-range>77.e9-77.e13</page-range>
            <pub-id pub-id-type="pmid">29097086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barbato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barth&#x000e9;l&#x000e9;my</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Dendale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dorobantu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edvardsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Folliguet</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Gilard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jobs</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lambrinou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Mehilli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meliga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roffi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rutten</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Sibbing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Siontis</surname>
                <given-names>GCM</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.</article-title>
            <source>Eur Heart J</source>
            <year>2021</year>
            <month>Apr</month>
            <day>07</day>
            <volume>42</volume>
            <issue>14</issue>
            <fpage>1289</fpage>
            <page-range>1289-1367</page-range>
            <pub-id pub-id-type="pmid">32860058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Gameren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lemmert</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wilschut</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Daemen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Jaegere</surname>
                <given-names>PPT</given-names>
              </name>
              <name>
                <surname>Zijlstra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Van Mieghem</surname>
                <given-names>NMDA</given-names>
              </name>
              <name>
                <surname>Diletti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>An update on the use of anticoagulant therapy in ST-segment elevation myocardial infarction.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>13</issue>
            <fpage>1441</fpage>
            <page-range>1441-1450</page-range>
            <pub-id pub-id-type="pmid">30185087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>132</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e17</page-range>
            <pub-id pub-id-type="pmid">29939938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douketis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Spyropoulos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Mayr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaffer</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Eckman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e326S</fpage>
            <page-range>e326S-e350S</page-range>
            <pub-id pub-id-type="pmid">22315266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>97</volume>
            <issue>31</issue>
            <fpage>e11384</fpage>
            <pub-id pub-id-type="pmid">30075504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nutescu</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fanikos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spinler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wittkowsky</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of anticoagulants used in the treatment of venous thromboembolism.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-31</page-range>
            <pub-id pub-id-type="pmid">26780737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Febbraro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leal Mart&#x000ed;nez-Bujanda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nieto Magro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bettica</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Bioavailability study of Enoxaparin Sodium Chemi (80 mg/0.8 mL) and Clexane (80&#x000a0;mg/0.8&#x000a0;mL) subcutaneous injection in healthy adults.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>11</issue>
            <fpage>734</fpage>
            <page-range>734-744</page-range>
            <pub-id pub-id-type="pmid">34402789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaikh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Regal</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Dosing of Enoxaparin in Renal Impairment.</article-title>
            <source>P T</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>245</fpage>
            <page-range>245-249</page-range>
            <pub-id pub-id-type="pmid">28381917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Balekian</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e195S</fpage>
            <page-range>e195S-e226S</page-range>
            <pub-id pub-id-type="pmid">22315261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Streiff</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Agnelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eichinger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McBane</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Moll</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Guidance for the treatment of deep vein thrombosis and pulmonary embolism.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-67</page-range>
            <pub-id pub-id-type="pmid">26780738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivera-Lebron</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McDaniel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahrar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alrifai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dudzinski</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Fanola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blais</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Janicke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Melamed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mohrien</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rozycki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Rali</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Teman</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Yarboro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ichinose</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bartos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Elder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keeling</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Palevsky</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Naydenov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amoroso</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rodriguez-Lopez</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Rosovsky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenfield</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kabrhel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Tapson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Channick</surname>
                <given-names>R</given-names>
              </name>
              <collab>PERT Consortium</collab>
            </person-group>
            <article-title>Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>25</volume>
            <fpage>1076029619853037</fpage>
            <pub-id pub-id-type="pmid">31185730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Creager</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>e362</fpage>
            <page-range>e362-425</page-range>
            <pub-id pub-id-type="pmid">23247304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amsterdam</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ganiats</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Kontos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Liebson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Smalling</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Zieman</surname>
                <given-names>SJ</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Dec</month>
            <day>23</day>
            <volume>130</volume>
            <issue>25</issue>
            <fpage>e344</fpage>
            <page-range>e344-426</page-range>
            <pub-id pub-id-type="pmid">25249585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gish</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Flamm</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulation in Patients With Chronic Liver Disease.</article-title>
            <source>Gastroenterol Hepatol (N Y)</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1 Suppl 1</issue>
            <fpage>10</fpage>
            <page-range>10-15</page-range>
            <pub-id pub-id-type="pmid">34135699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aursulesei</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Costache</surname>
                <given-names>II</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulation in chronic kidney disease: from guidelines to clinical practice.</article-title>
            <source>Clin Cardiol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>8</issue>
            <fpage>774</fpage>
            <page-range>774-782</page-range>
            <pub-id pub-id-type="pmid">31102275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Enoxaparin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>11</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">29999660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;nemann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Angchaisuksiri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dane</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>DeSancho</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Diuguid</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Klok</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Righini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanfilippo</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Skara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terrell</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Touri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Al Jabiri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Al Jabiri</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Boulos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Charide</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Colunga-Lozano</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Dearness</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Darzi</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Morgano</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Morsi</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Benitez</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Solo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wiercioch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Nieuwlaat</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients.</article-title>
            <source>Blood Adv</source>
            <year>2022</year>
            <month>Sep</month>
            <day>13</day>
            <volume>6</volume>
            <issue>17</issue>
            <fpage>4975</fpage>
            <page-range>4975-4982</page-range>
            <pub-id pub-id-type="pmid">35748885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arepally</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>May</month>
            <day>25</day>
            <volume>129</volume>
            <issue>21</issue>
            <fpage>2864</fpage>
            <page-range>2864-2872</page-range>
            <pub-id pub-id-type="pmid">28416511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lamani</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Goudar</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Kalburgi</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Bhavi</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Rectus Sheath Haematoma Secondary to Enoxaparin Injection- A Rare Case Report.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>PD11</fpage>
            <page-range>PD11-PD12</page-range>
            <pub-id pub-id-type="pmid">28511448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozdemir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dirikoc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ersoy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cakir</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy.</article-title>
            <source>Osteoporos Int</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>415</fpage>
            <page-range>415-8</page-range>
            <pub-id pub-id-type="pmid">25138263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <chapter-title>Low Molecular Weight Heparins</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>11</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31643341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uceda-Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miremont</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gaiffe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agier</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Studer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mah&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tebacher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cribier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Bullous haemorrhagic dermatitis induced by heparins and other anticoagulants: 94 cases from French pharmacovigilance centres and a literature review.</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>149</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-50</page-range>
            <pub-id pub-id-type="pmid">34175142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Legu&#x000ed;samo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prados Casta&#x000f1;o</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;ero Saavedra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cimbollek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recurrent Anaphylaxis Due to Enoxaparin.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2015</year>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>297</fpage>
            <page-range>297-9</page-range>
            <pub-id pub-id-type="pmid">26310046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gornik</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Fatal anaphylactoid reaction associated with heparin-induced thrombocytopenia.</article-title>
            <source>Vasc Med</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>136</fpage>
            <page-range>136-8</page-range>
            <pub-id pub-id-type="pmid">23579400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barcellona</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Melis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Floris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mameli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muroni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Defazio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marongiu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A "Catastrophic" Heparin-Induced Thrombocytopenia.</article-title>
            <source>Case Rep Med</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>6985020</fpage>
            <pub-id pub-id-type="pmid">32328108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridharan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Al Jufairi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al Daylami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Ansari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Qader</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pasha</surname>
                <given-names>SAA</given-names>
              </name>
            </person-group>
            <article-title>Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonates.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>1625</fpage>
            <page-range>1625-1640</page-range>
            <pub-id pub-id-type="pmid">32767900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Taee</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ghoulam</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Hachem</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and Anticoagulants.</article-title>
            <source>Dig Dis Sci</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>66</volume>
            <issue>10</issue>
            <fpage>3476</fpage>
            <page-range>3476-3481</page-range>
            <pub-id pub-id-type="pmid">33085015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Effect of enoxaparin on clinical events after percutaneous coronary intervention.</article-title>
            <source>Int J Clin Exp Med</source>
            <year>2015</year>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>10815</fpage>
            <page-range>10815-24</page-range>
            <pub-id pub-id-type="pmid">26379875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayad</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Hassanein</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Gohar</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Maternal and Fetal Outcomes in Pregnant Women with a Prosthetic Mechanical Heart Valve.</article-title>
            <source>Clin Med Insights Cardiol</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>11</fpage>
            <page-range>11-7</page-range>
            <pub-id pub-id-type="pmid">26884686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shehab</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lovegrove</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Weidle</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Budnitz</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Nov</month>
            <day>22</day>
            <volume>316</volume>
            <issue>20</issue>
            <fpage>2115</fpage>
            <page-range>2115-2125</page-range>
            <pub-id pub-id-type="pmid">27893129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tran</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Varfolomeev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic Enoxaparin Dosing in Obese Orthopedic Patients: A Literature Search.</article-title>
            <source>Hosp Pharm</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>366</fpage>
            <page-range>366-372</page-range>
            <pub-id pub-id-type="pmid">33245721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dybdahl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walliser</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pershing</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients.</article-title>
            <source>Clin Med Insights Blood Disord</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1179545X19863814</fpage>
            <pub-id pub-id-type="pmid">31360075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miranda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Cam-Duchez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Benichou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donnadieu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barbay</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Le Besnerais</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Delmas</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Cuvelier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000e9;vesque</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Benhamou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Armengol</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study.</article-title>
            <source>Thromb Res</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>155</volume>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">28460259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosencher</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Llau</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Mueck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Loewe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Homering</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).</article-title>
            <source>Acta Anaesthesiol Scand</source>
            <year>2013</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-72</page-range>
            <pub-id pub-id-type="pmid">23336294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarty</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.</article-title>
            <source>Ther Adv Cardiovasc Dis</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-49</page-range>
            <pub-id pub-id-type="pmid">26378211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seidel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tietke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heese</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Serious Complications After Epidural Catheter Placement: Two Case Reports.</article-title>
            <source>Local Reg Anesth</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>117</fpage>
            <page-range>117-124</page-range>
            <pub-id pub-id-type="pmid">34335056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashken</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Regional anaesthesia in patients at risk of bleeding.</article-title>
            <source>BJA Educ</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>84</fpage>
            <page-range>84-94</page-range>
            <pub-id pub-id-type="pmid">33664977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tahaineh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Edaily</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gharaibeh</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications.</article-title>
            <source>Clin Pharmacol</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>63</fpage>
            <page-range>63-70</page-range>
            <pub-id pub-id-type="pmid">29849468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Baglin</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Samama</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e24S</fpage>
            <page-range>e24S-e43S</page-range>
            <pub-id pub-id-type="pmid">22315264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahuja</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mousavi</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Klejmont</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Enoxaparin Dosing and AntiXa Monitoring in Specialty Populations: A Case Series of Renal-Impaired, Extremes of Body Weight, Pregnant, and Pediatric Patients.</article-title>
            <source>P T</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>609</fpage>
            <page-range>609-614</page-range>
            <pub-id pub-id-type="pmid">30271105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakakura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Momomura</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Safety of Reversing Anticoagulation by Protamine Following Elective Transfemoral Percutaneous Coronary Intervention in the Drug-Eluting Stent Era.</article-title>
            <source>Int Heart J</source>
            <year>2018</year>
            <month>May</month>
            <day>30</day>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>482</fpage>
            <page-range>482-488</page-range>
            <pub-id pub-id-type="pmid">29743410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalathottukaren</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Creagh</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Abbina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karbarz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Conley</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Kizhakkedathu</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.</article-title>
            <source>Blood Adv</source>
            <year>2018</year>
            <month>Aug</month>
            <day>28</day>
            <volume>2</volume>
            <issue>16</issue>
            <fpage>2104</fpage>
            <page-range>2104-2114</page-range>
            <pub-id pub-id-type="pmid">30135185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vatanparast</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lantz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Crilley</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Styler</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a pretest scoring system (4Ts) for the diagnosis of heparin-induced thrombocytopenia in a university hospital setting.</article-title>
            <source>Postgrad Med</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>124</volume>
            <issue>6</issue>
            <fpage>36</fpage>
            <page-range>36-42</page-range>
            <pub-id pub-id-type="pmid">23322137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Smythe</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Aslam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nazy</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT?</article-title>
            <source>Am J Hematol</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>96</volume>
            <issue>3</issue>
            <fpage>320</fpage>
            <page-range>320-329</page-range>
            <pub-id pub-id-type="pmid">33326124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colarossi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maffulli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Trivellas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schn&#x000f6;ring</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hatam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tingart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Migliorini</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis.</article-title>
            <source>Int J Clin Pharm</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>825</fpage>
            <page-range>825-838</page-range>
            <pub-id pub-id-type="pmid">33774764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21136.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pingleton</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Carlton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beasley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wittkopp</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moncure</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Reduction of venous thromboembolism (VTE) in hospitalized patients: aligning continuing education with interprofessional team-based quality improvement in an academic medical center.</article-title>
            <source>Acad Med</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>88</volume>
            <issue>10</issue>
            <fpage>1454</fpage>
            <page-range>1454-9</page-range>
            <pub-id pub-id-type="pmid">23969376</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
